Analysis Tools
immune system
|
• do not process caspase-1 and secrete less IL1B in response to LPS and ATP treatment
• impaired secretion of IL1A, IL1B and IL18 in TLR-primed and ATP-treated cells; however secretion of TNFA, IL6, and IL12 are similar to wild-type
• absence of bacterial muramyl dipeptide-stimulated IL1B secretion
|
|
• significant decrease in serum IL1B levels after challenge with 37.5 mg/kg of LPS
|
|
• significant decrease in serum IL18 levels after challenge with 37.5 mg/kg of LPS
|
|
• no difference in the degree of ear swelling between sensitized (with trinitrophenylchloride) and naive mice
|
|
• with lower doses of LPS (18.75 and 9.38 mg/kg) mortality is delayed or reduced, respectively, compared to wild-type mice
• however with a high dose of LPS ((37.5 mg/kg) no difference in the time course of incidence of mortality is seen and the time course of macrophage cell death in response to Salmonella tymphimurium is similar to wild-type
|
homeostasis/metabolism
|
• significant decrease in serum IL1B levels after challenge with 37.5 mg/kg of LPS
|
|
• significant decrease in serum IL18 levels after challenge with 37.5 mg/kg of LPS
|
hematopoietic system
|
• do not process caspase-1 and secrete less IL1B in response to LPS and ATP treatment
• impaired secretion of IL1A, IL1B and IL18 in TLR-primed and ATP-treated cells; however secretion of TNFA, IL6, and IL12 are similar to wild-type
• absence of bacterial muramyl dipeptide-stimulated IL1B secretion
|
